GFB 024
Alternative Names: GFB-024Latest Information Update: 28 Jun 2024
At a glance
- Originator Takeda
- Developer Goldfinch Bio
- Class Monoclonal antibodies; Urologics
- Mechanism of Action Cannabinoid receptor CB1 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic nephropathies; Focal segmental glomerulosclerosis
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Diabetic-nephropathies(In volunteers) in USA (Parenteral)
- 03 Jun 2022 Interim pharmacokinetics and adverse events data from a phase I trial in diabetic nephropathies presented at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA-2022)
- 08 Feb 2022 Goldfinch Bio completes a first-in-human phase I trial in Diabetic nephropathies (In volunteers) in USA (Parenteral) (NCT04880291)